Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-21
2007-08-21
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S012200, C530S350000
Reexamination Certificate
active
10794344
ABSTRACT:
Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
REFERENCES:
patent: 5484892 (1996-01-01), Tedder et al.
patent: 5506126 (1996-04-01), Seed et al.
patent: 5521288 (1996-05-01), Linsley et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5914112 (1999-06-01), Bednar et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 2002/0164697 (2002-11-01), Coyle et al.
patent: 2002/0177191 (2002-11-01), Kroczek
patent: 2002/0182667 (2002-12-01), Kroczek
patent: 2005/0261489 (2005-11-01), Kroczek
patent: 13320/99 (1999-04-01), None
patent: 19821060 (1999-04-01), None
patent: 0 984 023 (2000-03-01), None
patent: 1 125 585 (2001-08-01), None
patent: 11-228442 (1999-08-01), None
patent: 2000-154151 (2000-06-01), None
patent: WO95/33770 (1995-12-01), None
patent: WO97/26912 (1997-07-01), None
patent: WO98/11909 (1998-03-01), None
patent: WO98/19706 (1998-05-01), None
patent: WO98/37415 (1998-08-01), None
patent: WO98/38216 (1998-09-01), None
patent: WO98/45331 (1998-10-01), None
patent: WO 00/19988 (2000-04-01), None
patent: WO 00/46240 (2000-08-01), None
patent: WO 00/67788 (2000-11-01), None
patent: WO 01/08700 (2001-02-01), None
patent: WO 01/12658 (2001-02-01), None
patent: WO 01/15732 (2001-03-01), None
patent: WO 01/18022 (2001-03-01), None
patent: WO 01/21796 (2001-03-01), None
patent: WO 01/32675 (2001-05-01), None
patent: WO 01/64704 (2001-09-01), None
patent: WO 01/87981 (2001-11-01), None
patent: WO 02/44364 (2002-06-01), None
patent: WO 02/70010 (2002-09-01), None
patent: WO 02/76504 (2002-10-01), None
Riley et al., Blood, 2005, 105: 13-21.
Blazar et al., J. Immunol., 1996, 157: 3250-3259.
Rottman et al., Nature Immunology, 2001, 2: 605-611.
Vanderlugt et al., 2002, Nature Reviews Immunology, 2:85-95.
Huang Z., Pharmacology and Therapeutics, 2000, 86: 201-215.
Metzler et al., Nature Structural Biol. 1997; 4:527-531.
Sporici et al., Clinical Immunology, 2001, 100: 277-288; reference provided by Applicant.
Eljaschewitsch et al., “Identification of a novel activation antigen on human CD4+ T cells,” Immunobiol., 194(1-3):27 (1995).
Hutloff et al., “Identification and initial characterization of a novel T cell-specific cell surface activation antigen,” Immunobiol., 197(2-4):172 (1997).
Bajorath “A molecular model of inducible costimulator protein and three-dimensional analysis of its relation to the CD28 family of T cell-specific costimulator receptors,” J. Mol. Model. 5:169-176 (1999).
Bensimon et al., “Human lupus anti-DNA autoantibodies undergo essentially primary V kappa gene rearrangements,” EMBO J. 13(13):2951-62 (1994).
Buonfiglio et al., “Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas,” Eur. J. Immunol., 29(9)2863-2874 (1999).
Cocks et al. “A novel receptor involved in T-cell activation,” NATURE, 376:260-263 (Jul. 20, 1995).
Goding, “Monoclonal Antibodies: Principles and Practice,” 2ndEdition, Academic Press, Orlando, Florida, Chapter 8, pp. 281-293 (1986).
Goni et al., “Structural and idiotypic characterization of the L chains of human IgM autoantibodies with different specificities,” J. Immunol. 142(9):3158-63 (1989).
Harlow and Lane, “Antibodies: A Laboratory Manual,” Cold Spring Harbor Laboratory, p. 285 (1988).
Heyeck et al. “Developmental regulation of a murine T-cell-specific tyrosine kinase gene, Tsk,” Proc. Natl. Acad. Sci. USA, vol. 90, pp. 669-673 (1993).
Hutloff et al. “ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28,” NATURE 397:263-266 (1999).
Iiyama et al., “The role of inducible co-stimulator (ICOS)/B7-related protein-1 (B7RP-1) interaction in the functional development of Peyer's patches,” Immunology Letters, In Press, Uncorrected Proof available online Apr. 11, 2003, sciencedirect.com/science/journal/01652478.
Kuchroo et al. “B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy,” CELL, 80:707-718 (Mar. 10, 1995).
Mages et al. “Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand,” Eur. J. Immunol. 30:1040-1047 (2000).
Marguet et al. “cDNA Cloning for Mouse Thymocyte-activating Molecule,” The Journal of Biological Chemistry, vol. 267, No. 4, pp. 2200-2208 (1992).
Nojima et al. “The 4F9 antigen is a member of the tetra spans transmembrane protein family and functions as an accessory molecule in T cell activation and adhesion,” Cellular Immunology, 152:249-260 (1993).
Nurieva et al., “Inducible costimulator is essential for collagen-induced arthritis,” J. Clin. Invest. 111(5):701-06 (2003).
Özkaynak et al., “Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection,” Nature Immunology 2(7):591-596 (2001).
Pech et al., “A large section of the gene locus encoding human immunoglobulin variable regions of the kappa type is duplicated,” J. Mol Biol. 183(3):291-9 (1985).
Redoglia et al. “Characterization of H4: a mouse T lymphocyte activation molecule functionally associated with the CD3/T cell receptor,” Eur. J. Immunol., 26:2781-2789 (1996).
Robert et al. “Antibody Cross-Linking of the Thymocyte-Specific Cell Surface Molecule CTX Causes Abnormal Mitosis and Multinucleation of Tumor Cells,” Experimental Cell Research, 235:227-237 (1997).
Sakamoto et al., “AILIM/ICOS: its expression and functional analysis with monoclonal antibodies,” Hybridoma and Hybridomics, 20(5):293-303 (2001).
Sharpe “Analysis of lymphocyte costimulation in vivo using transgenic and ‘knockout ’mice,” Current Opinion in Immunology, 7:389-395 (1995).
Tai et al. “A role for CD9 molecules in T cell activation,” J. Exp. Med., 184:753-758 (Aug. 1996).
Tamatani et al., “Characteristics of an antibody which induces an ICAM-1-LFA-1-independent adhesion pathway,” Proceedings of the Japanese Society for Immunology, vol. 23, Abstract No. H-160 (1993) [Original Japanese and English Language Translation].
Tamatani et al. “AILIM/ICOS: a novel lymphocyte adhesion molecule,” International Immunology, 12(1):51-55 (2000).
Tezuka et al. “Identification and characterization of rat AILIM/ICOS, a novel T-cell costimulatory molecule, related to the CD28/CTLA4 family,” Biochemical and Biophysical Research Communications, 276:335-345 (2000).
Tomlinson et al., “The repertoire of human germline VH sequence reveals about fifty groups of VH segments with different hypervariable loops,” J. Mol. Biol. 227(3):776-98 (1992).
Aicher et al., “Characterization of Human Inducible Costimulator Ligand Expression and Function,” J. Immunol., 164(9):4689-4696 (2000).
Beier et al., “Induction, binding specificity and function of human ICOS,” Eur. J. Immunol., 30(12):3707-3717 (2000).
Brodie et al., “LICOS, a primordial costimulatory ligand?” Current Biology, 10(6):333-336 (2000).
Buonfiglio et al. “The T cell activation molecule H4 and the CD28-like molecule ICOS are identical,” Eur. J. Immunol., 30:3463-3467 (2000).
Cameron “Recent advances in transgenic technology” Molecular Biotechnology 7:253-65 (1997).
Chambers, “The expanding world of co-sti
Tamatani Takuya
Tezuka Katsunari
Fish & Richardson P.C.
Gambel Phillip
Japan Tobacco Inc.
Ouspenski Ilia
LandOfFree
Methods of treating multiple sclerosis with a JTT-1 polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating multiple sclerosis with a JTT-1 polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating multiple sclerosis with a JTT-1 polypeptide will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3891976